CEO of UnitedHealthcare, Brian Thompson, shot dead in New York City
Pharmaceutical Technology
DECEMBER 4, 2024
US police have confirmed that Brian Thompson was fatally shot outside an investor conference by a masked assailant.
Wed.Dec 04, 2024
147 
Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial
Bio Pharma Dive
DECEMBER 4, 2024
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Lilly’s Zepbound wins the weight loss duel with Novo’s Wegovy
Pharmaceutical Technology
DECEMBER 4, 2024
An open-label Phase III trial showed that participants using Zepbound saw 47% greater relative weight loss compared to Wegovy.
Antag, a startup backed by Versant and Novo, joins hunt for obesity drug alternatives
Bio Pharma Dive
DECEMBER 4, 2024
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide drug data.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Maze Therapeutics raises $115m to advance kidney disease candidates
Pharmaceutical Technology
DECEMBER 4, 2024
Maze Therapeutics has completed a Series D financing round, raising $115m to propel the development of its lead candidates, MZE829 and MZE782.
Atea plans Phase 3 study for hepatitis C drug after mid-stage results
Bio Pharma Dive
DECEMBER 4, 2024
The struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier treatment regimen.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Dewpoint, Mitsubishi partner on ALS drug in deal worth up to $480M
Bio Pharma Dive
DECEMBER 4, 2024
The collaboration is another vote of confidence in Dewpoint’s biomolecular condensates research, which had already attracted interest from the likes of Bayer and Novo Nordisk.
Takeda licensed for anaemia therapy by Keros Therapeutics
Pharmaceutical Technology
DECEMBER 4, 2024
Takeda has signed an agreement to receive an exclusive global licence from Keros Therapeutics for elritercept.
UnitedHealthcare CEO Brian Thompson fatally shot in NYC
Bio Pharma Dive
DECEMBER 4, 2024
The NYPD confirmed the shooting, which caused UnitedHealth to end an investor conference early on Wednesday. Thompson, 50, had been with UnitedHealth since 2004.
December 4, 2024: In This Week’s PCT Grand Rounds, Large Language Models for Postmarketing Surveillance of Medical Products
Rethinking Clinical Trials
DECEMBER 4, 2024
Dr. Michael Matheny In this Friday’s PCT Grand Rounds, Michael Matheny of Vanderbilt University will present “Opportunities and Challenges in the Use of Large Language Models for Postmarketing Surveillance of Medical Products.” The Grand Rounds session will be held on Friday, December 6, 2024, at 1:00 pm eastern. Matheny is a professor of biomedical informatics, biostatistics, and medicine and the director of the Center for Improving the Public’s Health Through Informatic
Novavax sells Czech plant to Novo; Relay licenses out a cancer drug
Bio Pharma Dive
DECEMBER 4, 2024
Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program and Takeda acquired a blood disease therapy.
Genmab expands its pipeline with $630m Scancell deal
pharmaphorum
DECEMBER 4, 2024
Genmab has licensed another anti-glycan antibody for cancer from UK biotech Scancell as it continues to expand its in-house pipeline.
Jupiter Neurosciences Makes Way in CNS Treatments with $11M IPO
XTalks
DECEMBER 4, 2024
Jupiter Neurosciences, a clinical-stage pharma company specializing in neuroinflammation, made its public market debut with an initial public offering (IPO) on the Nasdaq Capital Market under the symbol “JUNS.” The company priced 2,750,000 shares of common stock at $4.00 per share, expecting gross proceeds of $11 million. Trading began on December 3, 2024, with the IPO set to close the following day, subject to customary conditions.
Antag Therapeutics secures €80 million in weight loss therapy financing
Pharma Times
DECEMBER 4, 2024
Versant Ventures leads investment round to advance drug
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
How automating flow cytometry is revolutionising cancer diagnosis and treatment
pharmaphorum
DECEMBER 4, 2024
Discover how the automation of flow cytometry is transforming cancer diagnosis and treatment for breast, prostate, endometrial, pancreatic, kidney, and melanoma cancers. Explore the latest advancements in the field.
Everest therapy shows promise in nephropathy trial
Pharma Times
DECEMBER 4, 2024
Data highlights effectiveness of EVER001 in treating pMN
FDA signs off on Merus' first-in-class NRG1+ cancer drug Bizengri after brief delay
Fierce Pharma
DECEMBER 4, 2024
Merus’ week keeps getting better. | The FDA had originally pushed its decision back by three months after a November manufacturing-related delay.
Warning letter adds to Applied Tx run of bad news
pharmaphorum
DECEMBER 4, 2024
Applied Therapeutics gets a warning letter from the FDA over a trial of rare disease drug govorestat, which was rejected by the agency last week
With AstraZeneca exec under investigation in China, company names Reic new international chief
Fierce Pharma
DECEMBER 4, 2024
With AstraZeneca’s former international chief, Leon Wang, under investigation in China, the company has promoted an AZ veteran to fill the post. | With AstraZeneca’s former international chief, Leon Wang, under investigation in China, the company has promoted an AZ veteran to fill the post. The British giant has appointed Iskra Reic, Ph.D., as its new international executive vice president.
UK orders 5 million bird flu jabs for pandemic preparedness
pharmaphorum
DECEMBER 4, 2024
The UKHSA has taken steps to prepare for a possible bird flu outbreak by placing an order with Seqirus for millions of H5 vaccine doses
Targeting Cancer Drug Resistance with Kairos Pharma’s CEO Dr. John Yu
XTalks
DECEMBER 4, 2024
In this episode, Ayesha spoke with John Yu, MD, CEO of Kairos Pharma , a company advancing therapies to overcome challenges in cancer drug resistance and immune suppression. Kairos is developing therapeutics that reverse cancer drug resistance in cancers such as prostate and lung cancer. The company’s lead candidate, ENV105, is an antibody targeting CD105, which is implicated in cancer cell resistance to various treatments.
Zepbound tops Wegovy in first head-to-head weight-loss trial
pharmaphorum
DECEMBER 4, 2024
Eli Lilly's Zepbound beats Novo Nordisk's Wegovy in the first head-to-head trial comparing the two obesity drugs.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Optimizing Generic Drug Development with Machine Learning
Drug Patent Watch
DECEMBER 4, 2024
The pharmaceutical industry is undergoing a significant transformation with the advent of machine learning methods. These methods have the potential to revolutionize the drug discovery process by enhancing the efficiency and accuracy of identifying and developing new drug candidates.
Driving innovation in multiple myeloma to improve the patient experience
pharmaphorum
DECEMBER 4, 2024
Discover how driving innovation in multiple myeloma treatment can positively impact the patient experience. Stay informed on the latest advancements in cancer research and patient care.
Novo Nordisk keeps manufacturing expansion spree rolling with plans for $400M quality hub in Denmark
Fierce Pharma
DECEMBER 4, 2024
Amid a multi-year, multibillion-dollar spending spree to scale its global manufacturing capacity, Novo Nordisk is laying down fresh foundations at its old stomping grounds in Denmark to bolster a c | Novo will invest 2.9 billion Danish kroner (roughly $409 million) to construct a new, 53,000-square-meter quality control laboratory in Hillerød, Denmark.
MHRA's stature undermined by lack of resources says pharma
pharmaphorum
DECEMBER 4, 2024
The MHRA isn't sufficiently funded to meet its obligations and that could threaten UK investment in life sciences, according to an ABPI report
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Marketing Pharma: Proven Strategies to Stay Ahead in a Competitive Industry
Pharma Marketing Network
DECEMBER 4, 2024
Table of Contents Sr# Headings 1 Introduction 2 Understanding the Challenges in Marketing Pharma 3 Why Digital Transformation is Essential 4 Patient-Centric Marketing: Building Trust 5 Harnessing the Power of Omnichannel Marketing 6 Data-Driven Insights for Targeted Campaigns 7 Social Media in Pharma Marketing: Opportunities and Risks 8 AI and Automation: The Future of Marketing Pharma 9 Branded Content: Educate, Don’t Just Promote 10 Navigating Regulatory Hurdles 11 Sustainability: A Growing De
Brain-computer interfaces could redefine precision medicine
pharmaphorum
DECEMBER 4, 2024
Brain-computer interfaces, such as Elon Musk's Neuralink, have the potential to revolutionise precision medicine and transform how we understand and treat the brain. Learn more about this groundbreaking technology and its implications in healthcare.
Drug Patent Expirations for the Week of December 1, 2024
Drug Patent Watch
DECEMBER 4, 2024
SUMAVEL DOSEPRO (sumatriptan succinate) Endo operations Patent: 8,287,489 Expiration: Dec 6, 2024 See More … Source
Outcome measures: Patients beyond endpoints
pharmaphorum
DECEMBER 4, 2024
Learn about outcome measures that go beyond endpoints in drug development and treatment to better understand and assess the impact on patients. Explore the importance of considering patient perspectives in evaluating treatment outcomes.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content